GlassScriptPhysician profile
Albert T White
NPI 1588676696
$891.46
in general payments reported to CMS, 2019-2025
22 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $113 · 2021: $76.41 · 2022: $14.44 · 2023: $63.33 · 2024: $218 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100.37 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $88.39 | 2024-2025 | |
| Pfizer INC. | $82.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.70 | 2019-2025 | Imfinzi, Lynparza |
| Stemline Therapeutics INC. | $54.06 | 2025 | Orserdu |
| Blueprint Medicines Corporation | $48.91 | 2024-2025 | Ayvakit |
| Genentech USA, INC. | $47.12 | 2024-2025 | Tecentriq, Tecentriq Hybreza |
| Genzyme Corporation | $43.72 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $43.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $39.84 | 2020-2022 | |
| Celgene Corporation | $39.44 | 2019-2020 | |
| Allergan, INC. | $34.15 | 2019-2020 | |
| Geron Corporation | $27.21 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.64 | 2020 | |
| Pharmacosmos Therapeutics INC. | $24.26 | 2025 | Monoferric |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $21.46 | 2021 | |
| Janssen Biotech, INC. | $16.79 | 2021 | |
| Incyte Corporation | $16.54 | 2023 | Jakafi |
| Servier Pharmaceuticals LLC | $15.88 | 2024 | |
| Rigel Pharmaceuticals, INC. | $15.75 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Abbvie INC. | $15.66 | 2021 | |
| Eisai INC. | $14.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.